Zihan Xu and a team of researchers at the Laboratory of Single-Cell Genomics and Population Dynamics have developed a platform called PerturbFate that can do something previously impossible: watch hundreds of disease-causing genetic mutations alter cells in real time and identify the hidden control points where they all converge. The breakthrough, published in Nature, offers a new strategy for fighting diseases like cancer that are driven not by one or two genetic mistakes but by a bewildering array of them—and suggests that despite that complexity, there may be a far simpler way to treat them.
The challenge has haunted genetic medicine for years. Advances in DNA sequencing have allowed scientists to identify hundreds of mutations linked to cancer and other diseases, but that knowledge hasn't easily translated into cures. The problem is scope: these mutations do different jobs inside cells, affecting gene activity and cell signaling in seemingly unrelated ways. Designing a single treatment to counteract hundreds of different genetic causes has appeared nearly impossible. But Junyue Cao, head of the lab, suspected something else might be true—that these disparate mutations, despite their variety, might all funnel into shared downstream control systems. If so, a therapy wouldn't need to target every mutation separately. It could aim at the common regulatory hubs that actually drive the disease.
To test that theory, the team needed technology that could simultaneously disrupt hundreds or thousands of genes while watching in precise detail how each change reshaped a cell. Existing tools could only capture fragments of that picture, measuring one layer of cellular activity at a time and missing how gene activity evolved dynamically. Xu designed PerturbFate to bridge that gap, enabling researchers to observe DNA accessibility and RNA production in the same single cell, revealing the gene networks that control behavior and showing where different mutations produce identical downstream effects.
The researchers chose melanoma as their testing ground, selecting 143 genes previously linked to resistance against Vemurafenib, a widely used melanoma drug. They systematically disabled each gene in melanoma cells and watched what happened. PerturbFate tracked how each disruption changed cellular behavior over time, allowing scientists to separate newly produced RNA from older molecular signals and see which genes were active, which regions of DNA became accessible, and how those shifts evolved. By analyzing more than 300,000 individual cells, the team built detailed gene regulatory networks that connected early changes in transcription factor activity to later shifts in DNA accessibility and gene expression patterns.
The result was striking: many different mutations consistently pushed melanoma cells into the same drug-resistant state. That finding suggests a radical simplification. Instead of developing 143 different treatments for the 143 different mutations, researchers could target the shared regulatory control points that these mutations depend on—essentially treating the disease at its convergence point rather than at every source.
The implications extend far beyond melanoma. As Cao noted, the work addresses a fundamental question in genetic medicine: once you know a disease is associated with hundreds of genes, how do you design one therapy to treat it? PerturbFate offers a template. By revealing where disease-driving mutations converge, it points toward treatments that could work across many genetic causes at once—transforming a many-headed problem into one with a common solution.